Targeted drug therapy such as EGFR-TKI has demonstrated good clinical effects and has gradually become part of the clinical standard treatment of NSCLC, but it still faces optimal timing of targeted drug treatment, easy drug resistance, and the trade-off between the pros and cons of chemotherapy, etc (Goto et al., 2017; Lin et al., 2017; Nan et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.